Baseline and posttreatment clinical characteristics
| Patient clinical characteristics . | N = 41 . |
|---|---|
| Age-median (range, y) | 61 (25-77) |
| Males (%) | 61 |
| Number of prior therapies (median, range) | 3 (2-6) |
| Prior autologous stem cell transplantation (%) | 51 |
| Disease type | |
| DLBCL, no. (%) | 22 (53.7) |
| DLBCL transformed from indolent NHL, no. (%) | 13 (31.7) |
| Primary mediastinal B-cell lymphoma, no. (%) | 6 (14.6) |
| Type of therapy | |
| Axi-cel, no. (%) | 31 (75.6) |
| Tisa-cel, no. (%) | 10 (24.4) |
| CRS | |
| Grade 0, no. (%) | 10 (24.4) |
| Grade 1, no. (%) | 9 (22) |
| Grade 2-4, no. (%) | 22 (53.7) |
| Median time-to-CRS | 2 days (N = 31) |
| Median time to max. CRS | 4 days (N = 31) |
| ICANS | |
| Grade 0, no. (%) | 22 (53.7) |
| Grade 1, no. (%) | 9 (22) |
| Grade 2-4, no. (%) | 10 (24.4) |
| Median time-to-ICANS | 6 days (N = 19) |
| Median time to max. ICANS | 6 days (N = 19) |
| Treatments | |
| Use of tocilizumab, no. (%) | 23 (56) |
| Use of steroids, no. (%) | 13 (32) |
| 3-month response | Total (N = 39) |
| CR+PR, no. (%) | 19 (48.7) |
| CR, no. (%) | 14 (35.9) |
| SD, no. (%) | 2 (5.1) |
| PD, no. (%) | 13 (33.3) |
| Patient clinical characteristics . | N = 41 . |
|---|---|
| Age-median (range, y) | 61 (25-77) |
| Males (%) | 61 |
| Number of prior therapies (median, range) | 3 (2-6) |
| Prior autologous stem cell transplantation (%) | 51 |
| Disease type | |
| DLBCL, no. (%) | 22 (53.7) |
| DLBCL transformed from indolent NHL, no. (%) | 13 (31.7) |
| Primary mediastinal B-cell lymphoma, no. (%) | 6 (14.6) |
| Type of therapy | |
| Axi-cel, no. (%) | 31 (75.6) |
| Tisa-cel, no. (%) | 10 (24.4) |
| CRS | |
| Grade 0, no. (%) | 10 (24.4) |
| Grade 1, no. (%) | 9 (22) |
| Grade 2-4, no. (%) | 22 (53.7) |
| Median time-to-CRS | 2 days (N = 31) |
| Median time to max. CRS | 4 days (N = 31) |
| ICANS | |
| Grade 0, no. (%) | 22 (53.7) |
| Grade 1, no. (%) | 9 (22) |
| Grade 2-4, no. (%) | 10 (24.4) |
| Median time-to-ICANS | 6 days (N = 19) |
| Median time to max. ICANS | 6 days (N = 19) |
| Treatments | |
| Use of tocilizumab, no. (%) | 23 (56) |
| Use of steroids, no. (%) | 13 (32) |
| 3-month response | Total (N = 39) |
| CR+PR, no. (%) | 19 (48.7) |
| CR, no. (%) | 14 (35.9) |
| SD, no. (%) | 2 (5.1) |
| PD, no. (%) | 13 (33.3) |
CR, complete response; NHL, non-Hodgkin lymphoma; PD, progressive disease; PR, partial response; SD, stable disease.